amivantamab
janssen,genmab
['lcsm,(-blcsm)', 'chrysalis,(-chrysalis2),(-chrysalis-2),(-chrysalis 2)']
cohort d from the chrysalis trial (post-osi, chemo-naive) demonstrates that met ihc 3+ was predictive of response. is it any better than trying on oral tkis for this population? should we focus on met+ patients instead of the whole group? #asco23 #lcsm
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.